Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Tom Y.-H. Wu"'
Autor:
Kyle E. Korolowizc, Bin Li, Xu Huang, Changsuek Yon, Evelyn Rodrigo, Manny Corpuz, David M. Plouffe, Bhaskar V. Kallakury, Manasa Suresh, Tom Y.‐H. Wu, Andrew T. Miller, Stephan Menne
Publikováno v:
Hepatology Communications, Vol 3, Iss 10, Pp 1296-1310 (2019)
Current therapeutics for chronic infection with hepatitis B virus (HBV) rarely induce functional cure due to the immunotolerant status of patients. Small molecule agonists targeting toll‐like receptor 7 (TLR7) have been shown to elicit a functional
Externí odkaz:
https://doaj.org/article/f3ed15884f7a4b878fbb086e306253ac
Autor:
Zhihong Huang, Matthew S. Tremblay, Tom Y.-H. Wu, Qiang Ding, Xueshi Hao, Janine Baaten, Robert Hill, Bo Liu, Shelly Meeusen, Yefen Zou, Shanshan Yan, Yong Jia, Van Nguyen-Tran, Weijun Shen, Ganesh Bhat, Richard Glynne, Bryan Laffitte, Jing Li, Valentina Molteni, Yahu A. Liu
Publikováno v:
ACS Omega, Vol 4, Iss 2, Pp 3571-3581 (2019)
Externí odkaz:
https://doaj.org/article/5cf09ecffc814c04bc864f8859f4158a
Autor:
Tingting Mo, Yefen Zou, Weijun Shen, Zhihong Huang, Xiaoyue Zhang, Qihui Jin, Jing Li, Shifeng Pan, Michael Di Donato, Loren Jon, Andrew M. Schumacher, George Harb, Shanshan Yan, Anwesh Kamireddy, You-Qing Zhang, Tom Y.-H. Wu, Yong Jia, Xueshi Hao, Yahu A. Liu, Richard Glynne, Bryan Laffitte, Brandon Taylor, Peter McNamara, Qiang Ding, Wenqi Gao, Valentina Molteni, Badry Bursalaya, Lisa Deaton, Chun Li
Publikováno v:
ChemMedChem. 15:1562-1570
Loss of β-cell mass and function can lead to insufficient insulin levels and ultimately to hyperglycemia and diabetes mellitus. The mainstream treatment approach involves regulation of insulin levels; however, approaches intended to increase β-cell
Autor:
Bo Liu, Sukwon Ha, H. Michael Petrassi, Kate Jacobsen, George Harb, W. Perry Gordon, Bryan Laffitte, Thanh Lam, Qihui Jin, Yong Jia, Janine E. Baaten, Minhua Qiu, Robert Hill, Shelly Meeusen, Shanshan Yan, Badry Bursulaya, Valentina Molteni, Anwesh Kamireddy, Lisa Deaton, Jianfeng Pan, You-Qing Zhang, Loren Jon, Michael DiDonato, Yahu A. Liu, Shifeng Pan, Andrew M. Schumacher, Tingting Mo, Yefen Zou, Xiaoyue Zhang, Weijun Shen, Karyn Colman, Richard Glynne, Xueshi Hao, Peter McNamara, Vân Nguyen-Tran, Zhicheng Wang, Sheryll Espinola, Bao Nguyen, Tom Y.-H. Wu, Jing Li, Qiang Ding
Publikováno v:
Journal of Medicinal Chemistry. 63:2958-2973
Autoimmune deficiency and destruction in either β-cell mass or function can cause insufficient insulin levels and, as a result, hyperglycemia and diabetes. Thus, promoting β-cell proliferation could be one approach toward diabetes intervention. In
Autor:
Changsuek Yon, Xu Huang, Tom Y.-H. Wu, Bin Li, Manny Corpuz, David M. Plouffe, Kyle E. Korolowizc, Evelyn Rodrigo, Manasa Suresh, Bhaskar Kallakury, Stephan Menne, Andrew T. Miller
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 3, Iss 10, Pp 1296-1310 (2019)
Hepatology Communications, Vol 3, Iss 10, Pp 1296-1310 (2019)
Current therapeutics for chronic infection with hepatitis B virus (HBV) rarely induce functional cure due to the immunotolerant status of patients. Small molecule agonists targeting toll‐like receptor 7 (TLR7) have been shown to elicit a functional
Autor:
Ugo D'Oro, Chun Li, Kathy Yue, Michael P. Cooke, Janice Hampton, Andrew T. Miller, M. Lamine Mbow, Nicholas Valiante, David A. G. Skibinski, Xiaoyue Zhang, De Shon Hall, Michael Shapiro, Derek T. O'Hagan, Manmohan Singh, Tom Y.-H. Wu, Bishnu P. Nayak, Jillian Maginnis, Yongkai Li, Alex Cortez
Publikováno v:
Journal of Medicinal Chemistry. 59:5868-5878
Small molecule Toll-like receptor 7 (TLR7) agonists have been used as vaccine adjuvants by enhancing innate immune activation to afford better adaptive response. Localized TLR7 agonists without systemic exposure can afford good adjuvanticity, suggest
Publikováno v:
Cancer Research. 80:684-684
Anti-PD1/L1 has become the backbone of immune therapy for many cancer types. However, the majority of patients do not respond due to a myriad of mechanisms affecting the tumor microenvironment, including low tumor mutational burden and low immune cel
Autor:
Andrew T. Miller, Tom Y.-H. Wu, Luis Brito, Manmohan Singh, Derek T. O'Hagan, Rushit N. Lodaya, Gillis R. Otten
Publikováno v:
Journal of pharmaceutical sciences. 107(9)
Adjuvants are required to enhance immune responses to typically poorly immunogenic recombinant antigens. Toll-like receptor agonists (TLRa) have been widely evaluated as adjuvants because they activate the innate immune system. Currently, licensed va
Autor:
L. Arcidiacono, Derek T. O'Hagan, Simone Bufali, T. Uno, Fabio Rigat, Tom Y.-H. Wu, Sara Filippini, S. Vecchi
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 87:310-317
Next generation vaccine adjuvants include Toll like receptor agonists, which are mostly extracted from microorganisms, but synthetic small molecule TLR agonists have also been identified. However, their delivery systems have not been optimized for ef
Autor:
Richard Glynne, Bryan Laffitte, Peter McNamara, George Harb, Weidong Wang, V. Deshmukh, Matthew S. Tremblay, Charles Y. Cho, You Qing Zhang, Ann E. Herman, Peter G. Schultz, Jonathan G. Swoboda, Janine E. Baaten, Weijun Shen, Tom Y.-H. Wu, Christophe M. Filippi, Jing Li, Qihui Jin, Anwesh Kamireddy, Xu Wu
Publikováno v:
Journal of the American Chemical Society. 135:1669-1672
The identification of factors that promote β cell proliferation could ultimately move type 1 diabetes treatment away from insulin injection therapy and toward a cure. We have performed high-throughput, cell-based screens using rodent β cell lines t